Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder

Assessment Status Full HTA Assessment
Drug Pregabalin
Brand Lyrica®
Indication For the treatment of Generalised Anxiety Disorder.
Assessment Process
Full submission received from Applicant 12/09/2014
NCPE assessment completed 15/12/2014
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The NCPE Review Group concludes that, at the current price, pregabalin (Lyrica®) is not cost effective as a first line treatment for generalised anxiety disorder. Pregabalin may be considered cost effective (as a third line treatment) in patients who have relapsed or who have not responded to cognitive behavioural therapy (first line treatment) and who subsequently have relapsed or have not responded to escitalopram or venlaflaxine (first linedrug treatment).